Kymera Therapeutics, Inc. (KYMR)

The past six months have seen several events impacting Kymera Therapeutics' stock price. In December 2025, Kymera announced positive Phase 1b data for its oral STAT6 degrader KT-621 in patients with moderate to severe atopic dermatitis, leading to analyst price target upgrades. KT-621 received U.S. FDA Fast Track Designation for the treatment of atopic dermatitis. The company announced a proposed public offering, followed by the pricing and closing of an upsized $602 million public offering, which put pressure on the share price. In January 2026, Kymera outlined its 2026 objectives and clinical strategy. In June 2025, Kymera partnered with Gilead Sciences to develop a novel molecular glue degrader targeting CDK2 for oncology treatments. Analyst upgrades from major Wall Street firms followed promising Phase 1 data for KT-621, boosting investor confidence and causing shares to surge. The stock has experienced significant volatility, with a 6-month return of approximately 67.76% as of January 9, 2026. The share price as of January 9, 2026, was $74.77, representing a 100.89% increase over the price on January 13, 2025.

As a clinical-stage biopharmaceutical company, Kymera Therapeutics, Inc. does not currently have commercialized products generating sales revenue, therefore, traditional demand seasonality for products and services is not applicable. The company's revenue is 100% dependent on collaboration agreements and licensing deals with major pharmaceutical partners, which can be lumpy and driven by non-recurring milestone payments and upfront fees. While there is seasonal chart analysis available for the stock itself, indicating potential seasonal patterns in stock performance, this does not reflect seasonality in product demand.

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system, operating within the Health Care sector, specifically in the Biotechnology industry. Kymera's core business revolves around its proprietary Targeted Protein Degradation (TPD) platform, known as Pegasus, which aims to develop a new class of oral small molecule medicines. The company's pipeline is focused on immunology-inflammation and oncology. Major product candidates in Kymera's pipeline include KT-621 (STAT6 degrader) which is in Phase 2b development for atopic dermatitis and eosinophilic asthma and has received FDA Fast Track designation for atopic dermatitis, KT-579 (IRF5 degrader) which is expected to start a Phase 1 healthy volunteer trial in Q1 2026 and is being developed for autoimmune and inflammatory diseases, KT-485/SAR447971 (IRAK4 degrader) which is being advanced in partnership with Sanofi and is expected to enter Phase 1 in 2026, a CDK2 molecular glue degrader program under an agreement with Gilead Sciences, an MDM2 program targeting hematological malignancies and solid tumors, and a TYK2 program (KT-295) with a Phase 1 healthy volunteer study initiated in Q2 2025.

Kymera Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States, and operates across the US.

Kymera Therapeutics has a generally positive brand reputation, particularly within the scientific and investment communities, driven by its pioneering work in targeted protein degradation and promising clinical trial results. The company has been recognized as one of Boston's top workplaces for several years. Positive Phase 1b data for KT-621 and its FDA Fast Track designation have contributed to bullish analyst sentiment and increased investor confidence. While public offerings can cause short-term stock price pressure, they are also a sign of the company's ability to raise capital for continued development.

Kymera Therapeutics, Inc. has a significant institutional ownership with 450 institutional owners holding a total of 87,872,511 shares as of January 9, 2026. Major institutional owners include Baker Bros. Advisors Lp, Avoro Capital Advisors LLC, Fmr Llc, Bvf Inc/il, Vanguard Group Inc, Wellington Management Group Llp, Price T Rowe Associates Inc /md/, Atlas Venture Life Science Advisors, LLC, BlackRock, Inc., and Siren, L.L.C. Baker Bros Advisors LP is also noted as the largest individual Kymera Therapeutics shareholder, owning 7.96 million shares, representing 11.06% of the company. Insiders have bought more company stock than they have sold in the past three months.